Drug Pricing and Covid-19: Ralph Pisano Quoted in Forbes

Drug Pricing and Covid-19: Ralph Pisano Quoted in Forbes

RemedyOne president Ralph Pisano is quoted multiple times in a Forbes article titled Evaluating The Latest Treatment Options For Covid-19. The article concludes with his outlook for the future:

“It’s hard to overstate how much expanding beyond the vaccines with other methods of preventing hospitalization from Covid-19 will change the game,” he said. “The treatments will help ease the financial toll of the pandemic as well. Based on the rate the federal government is paying, Pfizer’s drug is priced at about $500 per patient. Merck’s comes in even higher at $700-800. While that may seem high, it is a small fraction of the cost of hospitalization and thus overall cost savings to the healthcare system.”

Vaccinated or not, the need for treatment may arise for all of us at some point. Because as Pisano put it, “Breakthrough cases have shown that vaccines alone aren’t enough to reign in the human or financial cost of the pandemic.”

Still, he hopes that the introduction of treatment options will help to put the fears surrounding Covid-19 to rest for good.

“2020 was the year of the shutdown,” he said. “2021 was the year of the vaccine. 2022 could be the year of the Covid treatment. Let’s hope 2023 is defined by something unrelated to the virus.”

It’s a goal we can all enter the new year with.

Read the full article in Forbes.

Featured Company
Focus Areas
  • Reducing Pharmacy Costs
Experts In This Article

Nick McLaughlin
CEO, Breeze

Share
Featuring Solutions For
Custom CTA designs for this insight
Get the latest digital download or fill out our contact form to talk to an expert about this type of content. This module is optional and meant to allow Insight pages to act as landing pages when appropriate contact form
Related Insights
Break up with the status quo

We’re igniting real change. From building and accelerating revolutionary healthcare businesses to delivering transformative tech and services to our clients, we’re raising the bar of what healthcare can be.

Ready to join us?